Literature DB >> 2344372

Role of endogenous sulfur-containing nucleophiles in an in vitro model of cis-diamminedichloroplatinum(II)-induced nephrotoxicity.

T J Montine1, R F Borch.   

Abstract

Quiescent LLC-PK1 cells have been shown to be a good model of cis-diamminedichloroplatinum(II) (DDP)-induced nephrotoxicity. In these nonproliferating porcine kidney epithelial cells, DDP inhibition of protein synthesis rate is the major correlate of cytotoxicity. We report here the use of this cell line to investigate the role of endogenous sulfur-containing nucleophiles in DDP-induced nephrotoxicity. Reaction of DDP with glutathione (GSH), cysteine, or methionine for up to 24 hr led to concentration- and time-dependent loss of its toxic effects, whereas dissolution of DDP alone did not alter its reduction of viability or protein synthesis rate in LLC-PK1 cells. Treatment of these cells with differing cytotoxic concentration of DDP produced an identical transient increase in intracellular GSH, whereas compounds known to bind GSH, trans-diamminedichloroplatinum(II) (t-DDP) and diethyl maleate (DEM), rapidly depleted LLC-PK1 intracellular GSH levels. Buthionine sulfoximine (BSO) treatment decreased intracellular GSH to 10% of control without altering cell viability or protein synthesis rate. However, BSO-pretreated LLC-PK1 cells exhibited enhanced DDP-induced toxicity. CdCl2 treatment produced a 30-fold induction of metallothionein-like, cadmium-binding proteins and a 10-fold increase in metallothionein isoform I (MT-I) mRNA, but this induction had no effect on DDP-induced reduction of viability or protein synthesis rate. Protracted DDP exposure did not induce MT-I mRNA levels in LLC-PK1 cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2344372     DOI: 10.1016/0006-2952(90)90121-z

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Involvement of nuclear factor-1 (NF1) binding motif in the regucalcin gene expression of rat kidney cortex: the expression is suppressed by cisplatin administration.

Authors:  H Misawa; M Yamaguchi
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  The transcriptional regulation of regucalcin gene expression.

Authors:  Masayoshi Yamaguchi
Journal:  Mol Cell Biochem       Date:  2010-10-11       Impact factor: 3.396

3.  Pituitary adenylate cyclase-activating polypeptide prevents cisplatin-induced renal failure.

Authors:  Min Li; Saravanan Balamuthusamy; Altaf M Khan; Jerome L Maderdrut; Eric E Simon; Vecihi Batuman
Journal:  J Mol Neurosci       Date:  2010-06-01       Impact factor: 3.444

4.  Suppressed expression of calcium-binding protein regucalcin mRNA in the renal cortex of rats with chemically induced kidney damage.

Authors:  H Kurota; M Yamaguchi
Journal:  Mol Cell Biochem       Date:  1995-10-04       Impact factor: 3.396

Review 5.  Regucalcin as a potential biomarker for metabolic and neuronal diseases.

Authors:  Masayoshi Yamaguchi
Journal:  Mol Cell Biochem       Date:  2014-03-06       Impact factor: 3.396

6.  Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model.

Authors:  D M Vail; A A Elfarra; A J Cooley; D L Panciera; E G MacEwen; S A Soergel
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Induction of autophagy in porcine kidney cells by quantum dots: a common cellular response to nanomaterials?

Authors:  Stephan T Stern; Banu S Zolnik; Christopher B McLeland; Jeffery Clogston; Jiwen Zheng; Scott E McNeil
Journal:  Toxicol Sci       Date:  2008-07-15       Impact factor: 4.849

9.  Cisplatin nephrotoxicity and protection by milk thistle extract in rats.

Authors:  Gholamreza Karimi; Mohammad Ramezani; Zahra Tahoonian
Journal:  Evid Based Complement Alternat Med       Date:  2005-07-26       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.